Guggenheim Upgrades MacroGenics (MGNX) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MGNX Hot Sheet
Price: $2.31 -0.86%
Rating Summary:
13 Buy, 9 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
13 Buy, 9 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Guggenheim analyst Charles Zhu upgraded MacroGenics (NASDAQ: MGNX) from Neutral to Buy with a price target of $12.00.
For an analyst ratings summary and ratings history on MacroGenics click here. For more ratings news on MacroGenics click here.
Shares of MacroGenics closed at $6.37 yesterday.
You May Also Be Interested In
- Northland Upgrades Astera Labs (ALAB) to Outperform
- Wells Fargo Upgrades Duolingo Inc. (DUOL) to Equal Weight
- Argus Upgrades Fiserv (FISV) to Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
